Clinical Trials Logo

Clinical Trial Summary

Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma


Clinical Trial Description

International, multicenter, comparative, open-label, parallel-group, mixed Observational-Randomized Controlled Trial. All the patients, who are candidate for the study will receive full information on the characteristics, potential effectiveness and side effects of the two alternatives treatments: radiotherapy (RT) and surgical treatment Eligible patients will be asked to be randomized in order to receive treatment A (surgery, with or without RT) or treatment B (definitive RT) Who will refuse randomization will be included in the Prospective Cohort Study (PCS) and will be treated accordingly to their choice (treatment option A or treatment option B). The same radiotherapy and surgical regimen will be administered in the PCS and in the Randomized Clinical Trial (RCT) cohort ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02986516
Study type Interventional
Source Italian Sarcoma Group
Contact Alessandro Gronchi, MD
Phone +390223903714
Email alessandro.gronchi@istitutotumori.mi.it
Status Recruiting
Phase N/A
Start date March 16, 2017
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT03595228 - BN Brachyury and Radiation in Chordoma Phase 2
Recruiting NCT06140732 - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT02383498 - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Phase 2
Recruiting NCT03242382 - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Phase 1
Active, not recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2
Completed NCT00713037 - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas N/A